Comprehensive analysis of cytokines and PD-L1 before and after administration of Atezolizumab and Bevasizumab in patients with HCC
Latest Information Update: 14 Feb 2022
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms ASTRAL-HCC
- 11 Feb 2022 Status changed from suspended to recruiting.
- 14 Jan 2022 Status changed from not yet recruiting to suspended.
- 06 Sep 2021 New trial record